Announcements
- Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™
- Cosmo Pharmaceuticals reports record results for 2022, preliminary results exceeding guidance, increased dividend distribution and 2023 guidance
Key statistics
As of last trade, Cosmo Pharmaceuticals NV (C43:FRA) traded at 54.50, 34.90% above the 52 week low of 40.40 set on Jun 15, 2022.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 54.00 |
---|---|
High | 54.50 |
Low | 54.00 |
Bid | 53.00 |
Offer | 54.50 |
Previous close | 54.00 |
Average volume | 1.40 |
---|---|
Shares outstanding | 17.54m |
Free float | 9.25m |
P/E (TTM) | 28.88 |
Market cap | 949.88m CHF |
EPS (TTM) | 1.87 CHF |
Annual div (ADY) | 0.95 EUR |
---|---|
Annual div yield (ADY) | 1.70% |
Div ex-date | Jun 01 2022 |
Div pay-date | Jun 03 2022 |
Data delayed at least 15 minutes, as of Mar 22 2023 13:45 BST.
More ▼